MTOR and breast carcinoma: Phase 1 and 2 clinical trials are currently ongoing to evaluate the asset of autophagy inhibitors alone [136,137,138] or together with other chemotherapeutic agents, such as microtubules inhibitors (taxane and taxane-like drugs) [139], mTOR inhibitor (everolimus) [140] and PI3K/mTOR inhibitors (gedatolisib) [141]) in breast cancer treatment.